Lansen Pharmaceutical Holdings Limited provided earnings guidance for the full year ended December 31, 2018. Based on the Group's preliminary review of the unaudited consolidated management accounts for the year ended 31 December 2018, the Group expects to record a noticeable decrease in its net profit for the year ended 31 December 2018 as compared with the net profit for the year ended 31 December 2017. The company is still in the process of finalizing the final results of the Group for the year ended 31 December 2018. The information contained in this announcement is only a preliminary assessment by the management of the company based on information currently available to the company, and is not based on any figure or information which has been audited or reviewed by the independent auditors of the Company nor approved by the audit committee of the company. The actual results of the Group for the year ended 31 December 2018 may be different from the financial information disclosed herein.